Home Investments Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation

Lyfebulb and Veloxis Pharmaceuticals Announce Finalists for 2022 Innovation Challenge in Organ Transplantation

by Ozva Admin

NEW YORK Y caryNorth Carolina, September 19, 2022 /PRNewswire/ — Lyfebulb, a patient empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 “Transforming Organ Transplantation Through “Innovation” Challenge.

“We are grateful for the opportunity to partner with Lyfebulb and are encouraged by the tremendous response to the Innovation Challenge and the solutions our finalists have developed for this unique patient population,” says Mark Hensley, CEO of Veloxis, an Asahi company. Kasei. “Veloxis shares their collective energy and dedication to the transplant community as we continue to invest in solving the many unmet needs that remain in transplant.”

The finalists, who were co-selected by the Lyfebulb and Veloxis Pharmaceuticals teams, have come up with promising innovations to improve the life experience and outcomes of transplant recipients and their loved ones. The potential impact on patients and their caregivers, as well as the viability and sustainability of the innovations in the market, were considerations in the selection of the following finalists:

  • isabel goalkeeperMD, PhD, CEO and Founder, Biohope Scientific Solutions for Human Health
  • Rory CunninghamDoctor, preclinical scientist, Ocher Bio
  • shaul dalton, CEO and Founder, OmniLife Health
  • Thomas Kledal, MD co-founder and CEO, Synklino A/S
  • Genevieve SpringerDoctor, founder and CEO, Organ-AI
  • Nick HousbyDoctor, co-founder and CEO, Accunea Ltd.
  • Jose ScaleaDoctor in medicine, co-founder and CMO, MediGO, Inc.
  • Chet Bennett, founder and executive director of the Alan C Foundation
  • Sharyn Kreitzer, founder and CEO, Donor Outreach for Veterans, Corp. (DOVE)
  • patrick scheetz, Founder and CEO, The Sweetest Gift

“We are very excited about the diverse group of finalists we have selected to work to bring innovation to transplantation,” said Karin Hehenberger, MD, PhD, Founder and CEO of Lyfebulb. “They have already shown strength in their commitment and creativity, and we look forward to the impact their work will have on patients and caregivers around the world.”

The finalists will be joined by industry leaders spanning business, venture capital and healthcare industries for a two-day summit at Cary, North Carolina Each finalist will present their solutions to a panel of judges who are experts in October 13-14, 2022. Judges include:

  • tough brandMD, PhD (Hon), FACSAuchincloss Professor of Surgery, Director Emeritus and Founder of the Transplant Program at Columbia New York-Presbyterian Hospital
  • Shelby Hansentransplant recipient, Lyfebulb patient ambassador and health coach
  • Howard KimDoctor in medicinemanaging director, corporate venture capital at Asahi Kasei America
  • Glenda Roberts, director of external relations and patient engagement at the University of Washington Kidney Research Institute/Center for Dialysis Innovation; director of strategy and operations – Center for Justice, Equity, Diversity and Inclusion
  • greg lewis, president and managing partner of Calcium

Prizes will be awarded to two finalists to further grow their businesses. The Innovation Award will be presented to a for-profit company and will include a $25,000 monetary grant. The Impact Prize will be awarded to a non-profit company and will include a $15,000 monetary grant.

To learn more about the Lyfebulb-Veloxis Innovation Challenge, visit Lyfebulb.com.

Veloxis Pharmaceuticals
Veloxis Pharmaceuticals, Inc, an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Based in cary north carolina, USA, Veloxis is focused on the development and global commercialization of medicines used by transplant patients and by patients with serious related illnesses. For more information, visit veloxis.com.

About Asahi Kasei
The Asahi Kasei Group contributes to life and the lives of people around the world. Since its founding in 1922 with the ammonia and cellulose fiber business, Asahi Kasei has grown steadily through proactively transforming its business portfolio to meet the changing needs of the times. With more than 40,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world’s challenges through its three business sectors Material, Home and Health. Its healthcare operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and biotherapeutic manufacturing, as well as pharmaceutical and diagnostic reagents. For more information, visit Asahi-Kasei.com.

About Lyfebulb
Lyfebulb is an innovation accelerator bridging the gap between patient communities and the healthcare industry by working directly with patients and care partners to generate insights and create new solutions to reduce the burden of living with chronic disease. The company operates two digital patient communities, TransplantLyfe and IBDLyfe. For more information visit Lyfebulb.com, TransplantLyfe.com, IBDlyfe.com, Instagram, LinkedIn, Twitter, FacebookY Karin Hehenberger personal LinkedIn.

For more information:

Veloxis Contact:
Caroline Barnhill
Oak and State Communications
[email protected]

Lyfebulb Contact:
Karin HehenbergerMD, PhD
CEO and Founder, Lyfebulb
Phone: + 1 917-575-0210
Email: [email protected]

SOURCE Lyfebulb

You may also like

Leave a Comment